Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00793572 · OUTCOME

Number of Patients Surviving Progression-free

Autologous or Syngeneic Stem Cell Transplant Followed by Donor Stem Cell Transplant and Bortezomib in Treating Patients With Newly Diagnosed High-Risk, Relapsed, or Refractory Multiple Myeloma · Source last updated 2020-01-22

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
COUNT_OF_PARTICIPANTS
Unit
Participants
Interval / dispersion
Not reported
Time frame
At 2 years after the autograft

What was measured

Number of subjects surviving without progressive disease post-transplant. Progressive disease criteria: 1. Greater than 25% increase in serum (absolute increase must be ≥0.5 g/dL) or urine (absolute increase must be ≥200 mg/24h) M proteins compared to best response status after autologous transplant. 2. Appearance of new lytic bone lesions or plasmacytomas.

Groups in this outcome

Tandem Auto-/Nonmyeloablative Allo-HCT and Maintenance Therapy

See Detailed Description Autologous Hematopoietic Stem Cell Transplantation: Undergo transplantation Bortezomib: Given SC Cyclosporine: Given IV Cyclosporine: Given PO Fludarabine Phosphate: Given IV Laboratory Biomarker Analysis: Correlative studies Melphalan: Given IV Mycophenolate Mofetil: Given PO Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation: Undergo transplantation Peripheral Blood Stem Cell Transplantation: Undergo transplantation Syngeneic Bone Marrow Transplantation: Undergo transplantation Total-Body Irradiation: Undergo radiotherapy

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Tandem Auto-/Nonmyeloablative Allo-HCT and Maintenance Therapy32

Reported measurements

Source class 1
Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Tandem Auto-/Nonmyeloablative Allo-HCT and Maintenance Therapy14Not reportedNot reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        value
        14
denoms
  1. counts
    1. group Id
      OG000
      value
      32
    units
    Participants
description
Number of subjects surviving without progressive disease post-transplant. Progressive disease criteria: 1. Greater than 25% increase in serum (absolute increase must be ≥0.5 g/dL) or urine (absolute increase must be ≥200 mg/24h) M proteins compared to best response status after autologous transplant. 2. Appearance of new lytic bone lesions or plasmacytomas.
groups
  1. description
    See Detailed Description Autologous Hematopoietic Stem Cell Transplantation: Undergo transplantation Bortezomib: Given SC Cyclosporine: Given IV Cyclosporine: Given PO Fludarabine Phosphate: Given IV Laboratory Biomarker Analysis: Correlative studies Melphalan: Given IV Mycophenolate Mofetil: Given PO Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation: Undergo transplantation Peripheral Blood Stem Cell Transplantation: Undergo transplantation Syngeneic Bone Marrow Transplantation: Undergo transplantation Total-Body Irradiation: Undergo radiotherapy
    id
    OG000
    title
    Tandem Auto-/Nonmyeloablative Allo-HCT and Maintenance Therapy
param Type
COUNT_OF_PARTICIPANTS
reporting Status
POSTED
time Frame
At 2 years after the autograft
title
Number of Patients Surviving Progression-free
type
PRIMARY
unit Of Measure
Participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice